Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml
Geburtshilfe Frauenheilkd 2019; 79(08): 780-785
DOI: 10.1055/a-0969-8243
DOI: 10.1055/a-0969-8243
DGGG
Mitteilungen aus der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG)
Berlin, 19.02.2019 – 279. Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) zu Abemaciclib (Mammakarzinom; Kombination mit einem Aromatasehemmer) – Nutzenbewertung gemäß § 35a SGB V
Further Information
Publication History
Publication Date:
12 August 2019 (online)
![](https://www.thieme-connect.de/media/gebfra/201908/lookinside/thumbnails/10-1055-a-0969-8243_gfm2019_08_dggg_04-1.jpg)
Im Namen der Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) e. V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG) geben wir zur Dossierbewertung A18-72 des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) nach kritischer Diskussion folgende Stellungnahme ab:
-
Literatur
- 1 Cardoso F, Senkus E, Costa A. et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4)†. Ann Oncol 2018; 29: 1634-1657 doi:10.1093/annonc/mdy192
- 2 Rugo HS, Rumble RB, Macrae E. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34: 3069-3103 doi:10.1200/JCO.2016.67.1487
- 3 Thill M, Liedtke C, Muller V. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018. Breast Care (Basel) 2018; 13: 209-215 doi:10.1159/000489331
- 4 AWMF. Leitlinie „Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms“. Registernummer 032–045OL. 2017. Online: http://www.awmf.org/uploads/tx_szleitlinien/032-045OLl_S3_Mammakarzinom_2017-12.pdf Stand: 19.02.2019
- 5 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646 doi:10.1200/JCO.2017.75.6155
- 6 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748 doi:10.1056/NEJMoa1609709
- 7 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936 doi:10.1056/NEJMoa1607303
- 8 Saad ED. Endpoints in advanced breast cancer: methodological aspects & clinical implications. Indian J Med Res 2011; 134: 413-418
- 9 Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-1649 doi:10.1093/jnci/djp369
- 10 Kaklamani VG. Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Oncologist 2016; 21: 922-930 doi:10.1634/theoncologist.2015-0366
- 11 Cortazar P, Justice R, Johnson J. et al. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol 2012; 30: 1705-1711 doi:10.1200/JCO.2011.39.2613
- 12 Muller V, Nabieva N, Haberle L. et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 2017; DOI: 10.1016/j.breast.2017.08.008.
- 13 Hurvitz SA, Lalla D, Crosby RD. et al. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. Breast Cancer Res Treat 2013; 142: 603-609 doi:10.1007/s10549-013-2734-4
- 14 Mouridsen H, Gershanovich M, Sun Y. et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-2109 doi:10.1200/JCO.2003.04.194
- 15 Nabholtz JM, Buzdar A, Pollak M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767 doi:10.1200/JCO.2000.18.22.3758
- 16 Bonneterre J, Thurlimann B, Robertson JF. et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757 doi:10.1200/JCO.2000.18.22.3748
- 17 Robertson JFR, Bondarenko IM, Trishkina E. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016; 388: 2997-3005 doi:10.1016/S0140-6736(16)32389-3
- 18 Zhang J, Huang Y, Wang C. et al. Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. Medicine (Baltimore) 2017; 96: e7846 doi:10.1097/MD.0000000000007846
- 19 Gibson L, Lawrence D, Dawson C. et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009; (04) CD003370 DOI: 10.1002/14651858.CD003370.pub3.
- 20 Muss HB, Wells HB, Paschold EH. et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis–a phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988; 6: 1098-1106 doi:10.1200/JCO.1988.6.7.1098
- 21 Muss HB, Case LD, Atkins JN. et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 1994; 12: 1630-1638 doi:10.1200/JCO.1994.12.8.1630
- 22 OʼShaughnessy J, Miles D, Vukelja S. et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823 doi:10.1200/JCO.2002.09.002
- 23 Sledge GW, Neuberg D, Bernardo P. et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21: 588-592 doi:10.1200/JCO.2003.08.013
- 24 Di Leo A, Jerusalem G, Petruzelka L. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28: 4594-4600 doi:10.1200/JCO.2010.28.8415
- 25 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219 doi:10.1056/NEJMoa1505270
- 26 Harbeck N, Iyer S, Turner N. et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 2016; 27: 1047-1054 doi:10.1093/annonc/mdw139
- 27 Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 2018; 10: 1758835918793326 doi:10.1177/1758835918793326
- 28 Hu W, Sung T, Jessen BA. et al. Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies. Clin Cancer Res 2016; 22: 2000-2008 doi:10.1158/1078-0432.CCR-15-1421
- 29 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Abemaciclib (Mammakarzinom; Kombination mit einem Aromatasehemmer) – Nutzenbewertung gemäß § 35a SGB V. Dossierbewertung A18–72. Version 1.0; 30.01.2019. Online: https://www.iqwig.de/de/projekte-ergebnisse/projekte/arzneimittelbewertung/2018/a18-72-abemaciclib-in-kombination-mit-einem-aromatasehemmer-mammakarzinom-nutzenbewertung-gemaess-35a-sgb-v.10908.html Stand: 19.02.2019